BIIB - Biogen Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
337.42
-0.92 (-0.27%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close338.34
Open340.33
Bid337.47 x 1100
Ask344.69 x 800
Day's Range334.71 - 340.55
52 Week Range249.17 - 388.67
Volume1,270,788
Avg. Volume1,360,324
Market Cap67.984B
Beta (3Y Monthly)1.81
PE Ratio (TTM)22.06
EPS (TTM)15.30
Earnings DateJan 29, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est385.37
Trade prices are not sourced from all markets
  • Which Big Pharma Stocks Lose Most in a War on Drug Price Hikes?
    Motley Fool8 hours ago

    Which Big Pharma Stocks Lose Most in a War on Drug Price Hikes?

    The answer: It's complicated.

  • Better Buy: Biogen vs. Gilead Sciences
    Motley Foolyesterday

    Better Buy: Biogen vs. Gilead Sciences

    Which stock wins in a battle between these two big biotechs?

  • Markityesterday

    See what the IHS Markit Score report has to say about Biogen Inc.

    # Biogen Inc ### NASDAQ/NGS:BIIB View full report here! ## Summary * ETFs holding this stock are seeing positive inflows but are weakening * Bearish sentiment is low ## Bearish sentiment Short interest | Positive Short interest is extremely low for BIIB with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting BIIB. ## Money flow ETF/Index ownership | Negative ETF activity is negative and may be weakening. The net inflows of $6.44 billion over the last one-month into ETFs that hold BIIB are among the lowest of the last year and appear to be slowing. ## Economic sentiment PMI by IHS Markit | Neutral According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, but is easing. ## Credit worthiness Credit default swap CDS data is not available for this security. Please send all inquiries related to the report to score@ihsmarkit.com. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • These 3 Biotech Stocks Appear Poised To Beat Fourth-Quarter Forecasts
    Investor's Business Daily2 days ago

    These 3 Biotech Stocks Appear Poised To Beat Fourth-Quarter Forecasts

    Biotech stocks Gilead Sciences, Biogen and Celgene are set to beat some aspects of Q4 earnings estimates, an analyst predicted, saying he expects conservative guidance.

  • Top Stock Reports for Pfizer, Biogen & Schwab
    Zacks2 days ago

    Top Stock Reports for Pfizer, Biogen & Schwab

    Top Stock Reports for Pfizer, Biogen & Schwab

  • Will Biogen (BIIB) Beat Estimates Again in Its Next Earnings Report?
    Zacks3 days ago

    Will Biogen (BIIB) Beat Estimates Again in Its Next Earnings Report?

    Biogen (BIIB) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

  • Markit5 days ago

    See what the IHS Markit Score report has to say about Biogen Inc.

    # Biogen Inc ### NASDAQ/NGS:BIIB View full report here! ## Summary * Bearish sentiment is low ## Bearish sentiment Short interest | Positive Short interest is extremely low for BIIB with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting BIIB. ## Money flow ETF/Index ownership | Neutral ETF activity is neutral. ETFs that hold BIIB had net inflows of $13.20 billion over the last one-month. While these are not among the highest inflows of the last year, the rate of inflow is increasing. ## Economic sentiment PMI by IHS Markit | Neutral According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, but is easing. ## Credit worthiness Credit default swap CDS data is not available for this security. Please send all inquiries related to the report to score@ihsmarkit.com. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Will Biogen Jump On This Biotech Stock Amid Buying Spree?
    Investor's Business Daily6 days ago

    Will Biogen Jump On This Biotech Stock Amid Buying Spree?

    Alder Biopharmaceuticals could eventually capture 15%-20% of the market for migraine prevention, an analyst said Monday, suggesting the biotech stock might be a good fit for giant Biogen.

  • Biogen Could Spend Nearly $18 Billion In A Takeover — But Will It?
    Investor's Business Daily10 days ago

    Biogen Could Spend Nearly $18 Billion In A Takeover — But Will It?

    Biogen could spend nearly $18 billion in a takeover, an analyst estimated Thursday after the biotech giant said it could become acquisitive in 2019. Biogen typically seeks early-stage deals.

  • Value Added: 7 Top Stocks for 2019
    Kiplinger11 days ago

    Value Added: 7 Top Stocks for 2019

    Making money in the stock market this year is going to take all the skill and luck you can muster. The global economy is slowing, a trade war with China still lingers despite negotiations, and the Federal Reserve remains likely to raise short-term interest rates, albeit slowly. But you still can find promising investments. To identify some of the top stocks right now, I interviewed Jerome Dodson, manager of Parnassus Endeavor Fund (PARWX) and founder of the Parnassus funds. Based in San Francisco, Parnassus is the largest U.S. fund firm focused on buying good stocks that are also, in the firm's view, good corporate citizens in terms of the environment, social and corporate governance issues. More to the point, Dodson's fund has a first-class record. Endeavor returned an annualized 16.3% over the past 10 years - an average of 3.1 percentage points per year better than the Standard & Poor's 500-stock index. Dodson, 75, is a contrarian investor who loves to pounce on stocks that have been pummeled. Given the selloff, this is precisely Dodson's kind of market. Read on for his seven top stocks for 2019. ### SEE ALSO: 19 Best Retirement Stocks to Buy in 2019

  • Biotech Stock Roundup: LOXO, CELG Gain, J.P. Morgan Healthcare Conference in Focus
    Zacks11 days ago

    Biotech Stock Roundup: LOXO, CELG Gain, J.P. Morgan Healthcare Conference in Focus

    It was a busy week for the biotech sector with most companies gaining on M&A activity. The annual J.P. Morgan Healthcare conference were also a key area of focus.

  • Markit11 days ago

    See what the IHS Markit Score report has to say about Biogen Inc.

    # Biogen Inc ### NASDAQ/NGS:BIIB View full report here! ## Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is low ## Bearish sentiment Short interest | Positive Short interest is extremely low for BIIB with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting BIIB. ## Money flow ETF/Index ownership | Positive ETF activity is positive. Over the last month, ETFs holding BIIB are favorable, with net inflows of $17.43 billion. Additionally, the rate of inflows is increasing. ## Economic sentiment PMI by IHS Markit | Neutral According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, but is easing. ## Credit worthiness Credit default swap CDS data is not available for this security. Please send all inquiries related to the report to score@ihsmarkit.com. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • The 10 Best Health-Care Stocks to Buy for 2019
    Kiplinger12 days ago

    The 10 Best Health-Care Stocks to Buy for 2019

    Health-care stocks were the best sector in the Standard & Poor's 500-stock index in 2018, according to Yardeni Research. The sector's 4.7% gain last year isn't exactly eye-popping. But consider that utilities (+0.5%) were the only sector in the black, and that the index itself lost 6.2% ... and you realize just how impressive health care actually was. As we look ahead to 2019, economic storm clouds appear to be gathering. Although a recession is unlikely in the year ahead, UCLA economists estimate that GDP growth will shrink from 3% in 2018 to 2% in 2019 and finally 1% in 2020. Thus, in the potential absence of a good offense, it makes sense for investors to buy some defense in 2019. The best health-care stocks can fit that bill. "Health care is a defensive growth sector that we think should have a growth upturn over the next five years or so," Saira Malik, head of global equities at Nuveen, told Fortune in November. With that in mind, here are 10 health-care stocks to buy for 2019. ### SEE ALSO: 101 Best Dividend Stocks to Buy for 2019 and Beyond

  • Markit12 days ago

    See what the IHS Markit Score report has to say about Biogen Inc.

    # Biogen Inc ### NASDAQ/NGS:BIIB View full report here! ## Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is low * Economic output in this company's sector is expanding ## Bearish sentiment Short interest | Positive Short interest is extremely low for BIIB with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting BIIB. ## Money flow ETF/Index ownership | Positive ETF activity is positive. Over the last month, ETFs holding BIIB are favorable, with net inflows of $17.43 billion. Additionally, the rate of inflows is increasing. ## Economic sentiment PMI by IHS Markit | Positive According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year. ## Credit worthiness Credit default swap CDS data is not available for this security. Please send all inquiries related to the report to score@ihsmarkit.com. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Biogen Inks Two Deals to Make Drugs for Neurological Diseases
    Zacks13 days ago

    Biogen Inks Two Deals to Make Drugs for Neurological Diseases

    Biogen (BIIB) signs deals with C4 Therapeutics and Skyhawk Therapeutics to develop potential therapies for Alzheimer's disease (AD), Parkinson's disease and other neurological diseases.

  • Reuters14 days ago

    BRIEF-Samsung Biologics’ JV Samsung Bioepis Partners With Chinese Biopharma 3SBio

    Jan 7 (Reuters) - Samsung Bioepis, a joint venture between Samsung BioLogics and Biogen, in a press release: * SAYS FORMS PARTNERSHIP WITH CHINESE BIOPHARMA 3SBIO Further company coverage:

  • All the Pre-JPM News Healthcare Investors Need to Know
    Motley Fool14 days ago

    All the Pre-JPM News Healthcare Investors Need to Know

    The Super Bowl of biotech kicked off early for these companies.

  • Markit15 days ago

    See what the IHS Markit Score report has to say about Biogen Inc.

    This could indicate that investors who seek to profit from falling equity prices are not currently targeting BIIB. According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way.

  • Biogen Begins Improved Dosing Regimen on Tysabri in Phase III
    Zacks16 days ago

    Biogen Begins Improved Dosing Regimen on Tysabri in Phase III

    Biogen (BIIB) commences enrollment in late-stage study to evaluate an expanded interval dosing of its MS drug, Tysabri, in patients with relapsing MS.

  • Biogen doubles down on Alzheimer's with new collaboration deal
    American City Business Journals16 days ago

    Biogen doubles down on Alzheimer's with new collaboration deal

    The Cambridge drugmaker already has several Alzheimer's drugs in the works, a risky strategy given that other major pharmaceutical firms have seen late-stage trials fail in recent years.

  • Biogen and Skyhawk Therapeutics Announce Agreement to Develop Novel Small Molecule RNA Splicing Modifiers for Neurological Disease Targets
    PR Newswire16 days ago

    Biogen and Skyhawk Therapeutics Announce Agreement to Develop Novel Small Molecule RNA Splicing Modifiers for Neurological Disease Targets

    CAMBRIDGE, Mass. and WALTHAM, Mass., Jan. 4, 2019 /PRNewswire/ -- Biogen Inc (BIIB) and Skyhawk Therapeutics, Inc. (Skyhawk) today announced a strategic collaboration in which the companies will leverage Skyhawk's SkySTAR™ technology platform with the goal of discovering innovative small molecule treatments for patients with neurological diseases. Biogen will have the option to license therapies resulting from the collaboration and will be responsible for their development and potential commercialization.

  • GlobeNewswire16 days ago

    Biogen and C4 Therapeutics Enter into Strategic Collaboration to Discover and Develop Potential New Treatments for Neurological Conditions

    Biogen Inc (BIIB) and C4 Therapeutics (C4T) announced today that they have entered into a strategic collaboration to investigate the use of C4T’s novel protein degradation platform to discover and develop potential new treatments for neurological conditions, such as Alzheimer’s disease and Parkinson’s disease. Under the agreement, C4T will provide expertise and research services in targeted protein degradation and Biogen will provide neuroscience expertise and drug development capabilities.

  • GlobeNewswire16 days ago

    Biogen and Skyhawk Therapeutics Announce Agreement to Develop Novel Small Molecule RNA Splicing Modifiers for Neurological Disease Targets

    Biogen Inc (BIIB) and Skyhawk Therapeutics, Inc. (Skyhawk) today announced a strategic collaboration in which the companies will leverage Skyhawk’s SkySTAR™ technology platform with the goal of discovering innovative small molecule treatments for patients with neurological diseases. Biogen will have the option to license therapies resulting from the collaboration and will be responsible for their development and potential commercialization.

  • Are Biogen Inc.’s (NASDAQ:BIIB) Interest Costs Too High?
    Simply Wall St.16 days ago

    Are Biogen Inc.’s (NASDAQ:BIIB) Interest Costs Too High?

    Investors seeking to preserve capital in a volatile environment might consider large-cap stocks such as Biogen Inc. (NASDAQ:BIIB) a safer option. Risk-averse investors who are attracted to diversified streams of Read More...

  • GlobeNewswire17 days ago

    First Patient Enrolled in Biogen’s Phase 3b Study to Evaluate Extended Interval Dosing (EID) with Natalizumab in Multiple Sclerosis

    Currently commercialized under the brand name TYSABRI®, natalizumab 300 mg dosed every four weeks is the only approved dosing regimen. Patients who switch to EID after one year of treatment with natalizumab SID will be evaluated in relation to patients receiving continued SID treatment. “For more than a decade, natalizumab has been considered a highly effective treatment option for patients with relapsing forms of MS,” said Alfred Sandrock, Jr., M.D., Ph.D., executive vice president and chief medical officer at Biogen.